Michelle L. Kramer
Janssen Scientific Affairs (United States) · 34 works · 2,603 citations · h-index 18
Top works
- Treatment of schizophrenia with paliperidone extended-release tablets: A 6-week placebo-controlled trial☆
- Paliperidone Extended-Release Tablets for Prevention of Symptom Recurrence in Patients With Schizophrenia
- Efficacy and Safety of Paliperidone Extended-Release Tablets: Results of a 6-Week, Randomized, Placebo-Controlled Study
- Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): Results of a 6-week, randomized, placebo-controlled study
- Rapid Antimanic Effect of Risperidone Monotherapy: A 3-Week Multicenter, Double-Blind, Placebo-Controlled Trial
- Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study
- Risperidone in the treatment of acute mania
- Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol
- Efficacy and Tolerability of Oral Paliperidone Extended-Release Tablets in the Treatment of Acute Schizophrenia
- Efficacy of olanzapine in social anxiety disorder: a pilot study
- Safety and Tolerability of Oral Paliperidone Extended-Release Tablets in Elderly Patients With Schizophrenia: A Double-Blind, Placebo-Controlled Study With Six-Month Open-Label Extension
- Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies
- Symptomatic Remission in Patients With Bipolar Mania
- Translational Evaluation of JNJ-18038683, a 5-Hydroxytryptamine Type 7 Receptor Antagonist, on Rapid Eye Movement Sleep and in Major Depressive Disorder
- A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophrenia
- Evaluation of the effect of paliperidone extended release and quetiapine on corrected QT intervals
- Delaying symptom recurrence in patients with schizophrenia with paliperidone extended-release tablets: an international, randomized, double-blind, placebo-controlled study (PAL-SCH-301)
- One-Year Open-Label Safety and Efficacy Study of Paliperidone Extended-Release Tablets in Patients With Schizophrenia
- Novel Benzamide-Based Histamine H3 Receptor Antagonists: The Identification of Two Candidates for Clinical Development
- 322 – Efficacy/tolerability of paliperidone palmitate: 9-week, placebo-controlled study in schizophrenia patients